Clarivate (CLVT)
Market Price (2/5/2026): $2.25 | Market Cap: $1.5 BilSector: Information Technology | Industry: IT Consulting & Other Services
Clarivate (CLVT)
Market Price (2/5/2026): $2.25Market Cap: $1.5 BilSector: Information TechnologyIndustry: IT Consulting & Other Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% | Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -152% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 287% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -44% | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.5% | |
| Attractive yieldFCF Yield is 23% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% | |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, Precision Medicine, and Digital Health & Telemedicine. Themes include AI Software Platforms, Show more. | Key risksCLVT key risks include [1] a substantial debt burden and associated liquidity concerns, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 24%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -44% |
| Attractive yieldFCF Yield is 23% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, Precision Medicine, and Digital Health & Telemedicine. Themes include AI Software Platforms, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -118%, 3Y Excs Rtn is -152% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 287% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -3.0%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -0.5% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -31% |
| Key risksCLVT key risks include [1] a substantial debt burden and associated liquidity concerns, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Deteriorating Analyst Sentiment and Price Target Reductions. Clarivate experienced significant downgrades and reductions in price targets from multiple financial institutions during the period. Morgan Stanley reissued an "underweight" rating and lowered its price target from $5.00 to $3.00 in mid-December 2025. Similarly, The Goldman Sachs Group downgraded Clarivate from a "buy" to a "neutral" rating and reduced its price objective from $4.20 to $3.60 in early January 2026. Other firms, including Wall Street Zen and Weiss Ratings, also lowered their ratings to "hold" or "sell." This collective shift in analyst outlook contributed to a loss of investor confidence in the company's near-term prospects.
2. Persistent Profitability Concerns and Slow Revenue Growth. Despite exceeding some analyst expectations in its Q3 2025 earnings report, a prevailing narrative highlighted Clarivate's ongoing unprofitability and slow projected revenue growth. An October 2025 analysis indicated that Clarivate remained unprofitable, with losses increasing over the prior five years and no improvement in net profit margin, even though future earnings were forecast to surge. Concerns about whether anticipated margin improvements and cost savings would materialize as expected, alongside projected negative revenue growth for fiscal years 2025 and 2026, continued to weigh on investor sentiment. Additionally, the consensus EPS forecast for Q4 2025 showed a projected year-over-year decline.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.2% change in CLVT stock from 10/31/2025 to 2/4/2026 was primarily driven by a -36.2% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 2042026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.40 | 2.17 | -36.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,501 | 2,501 | 0.0% |
| P/S Multiple | 0.9 | 0.6 | -36.2% |
| Shares Outstanding (Mil) | 668 | 668 | 0.0% |
| Cumulative Contribution | -36.2% |
Market Drivers
10/31/2025 to 2/4/2026| Return | Correlation | |
|---|---|---|
| CLVT | -36.2% | |
| Market (SPY) | 0.6% | 36.8% |
| Sector (XLK) | -8.1% | 24.0% |
Fundamental Drivers
The -43.6% change in CLVT stock from 7/31/2025 to 2/4/2026 was primarily driven by a -44.7% change in the company's P/S Multiple.| (LTM values as of) | 7312025 | 2042026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.85 | 2.17 | -43.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,500 | 2,501 | 0.0% |
| P/S Multiple | 1.0 | 0.6 | -44.7% |
| Shares Outstanding (Mil) | 681 | 668 | 1.9% |
| Cumulative Contribution | -43.6% |
Market Drivers
7/31/2025 to 2/4/2026| Return | Correlation | |
|---|---|---|
| CLVT | -43.6% | |
| Market (SPY) | 8.9% | 39.3% |
| Sector (XLK) | 5.3% | 24.1% |
Fundamental Drivers
The -60.0% change in CLVT stock from 1/31/2025 to 2/4/2026 was primarily driven by a -61.6% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2042026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.42 | 2.17 | -60.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,577 | 2,501 | -3.0% |
| P/S Multiple | 1.5 | 0.6 | -61.6% |
| Shares Outstanding (Mil) | 719 | 668 | 7.5% |
| Cumulative Contribution | -60.0% |
Market Drivers
1/31/2025 to 2/4/2026| Return | Correlation | |
|---|---|---|
| CLVT | -60.0% | |
| Market (SPY) | 15.0% | 52.9% |
| Sector (XLK) | 20.2% | 45.6% |
Fundamental Drivers
The -80.5% change in CLVT stock from 1/31/2023 to 2/4/2026 was primarily driven by a -80.3% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2042026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.12 | 2.17 | -80.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,545 | 2,501 | -1.7% |
| P/S Multiple | 2.9 | 0.6 | -80.3% |
| Shares Outstanding (Mil) | 674 | 668 | 0.8% |
| Cumulative Contribution | -80.5% |
Market Drivers
1/31/2023 to 2/4/2026| Return | Correlation | |
|---|---|---|
| CLVT | -80.5% | |
| Market (SPY) | 75.1% | 39.5% |
| Sector (XLK) | 107.3% | 30.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CLVT Return | -21% | -65% | 11% | -45% | -34% | -37% | -93% |
| Peers Return | 37% | -20% | 32% | 13% | -12% | -17% | 20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 1% | 84% |
Monthly Win Rates [3] | |||||||
| CLVT Win Rate | 50% | 25% | 33% | 33% | 42% | 0% | |
| Peers Win Rate | 72% | 38% | 65% | 50% | 48% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CLVT Max Drawdown | -30% | -66% | -26% | -53% | -39% | -37% | |
| Peers Max Drawdown | -11% | -32% | -2% | -8% | -23% | -17% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TRI, SPGI, MCO, VRSK, FDS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/4/2026 (YTD)
How Low Can It Go
| Event | CLVT | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -81.5% | -25.4% |
| % Gain to Breakeven | 440.8% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -28.2% | -33.9% |
| % Gain to Breakeven | 39.4% | 51.3% |
| Time to Breakeven | 32 days | 148 days |
| 2018 Correction | ||
| % Loss | -11.1% | -19.8% |
| % Gain to Breakeven | 12.5% | 24.7% |
| Time to Breakeven | 33 days | 120 days |
Compare to TRI, SPGI, MCO, VRSK, FDS
In The Past
Clarivate's stock fell -81.5% during the 2022 Inflation Shock from a high on 6/7/2021. A -81.5% loss requires a 440.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Clarivate (CLVT)
AI Analysis | Feedback
Here are 1-2 brief analogies for Clarivate (CLVT):
- Bloomberg for scientific and intellectual property intelligence.
- LexisNexis for research publications and patent management.
AI Analysis | Feedback
- Academic & Government Research Solutions: Provides researchers with critical data, analytics, and workflow tools to discover, track, and evaluate research.
- Life Sciences & Healthcare Solutions: Offers intelligence, data, and analytics for drug discovery, clinical development, and commercialization in the pharmaceutical and biotech industries.
- Intellectual Property Solutions: Delivers patent, trademark, and domain intelligence, as well as brand protection and enforcement services.
- Industry Standards & Technical Information: Supplies access to a vast collection of industry standards and technical codes.
AI Analysis | Feedback
Clarivate (CLVT) primarily sells its products and services to other companies and institutions (B2B).
Due to its diversified, subscription-based business model, Clarivate serves tens of thousands of organizations globally. As a result, no single customer or a small group of customers accounts for a material portion of its revenue, and specific major customer companies are not publicly disclosed. Instead, Clarivate's major customers can be identified by the key categories of organizations it serves:
- Academic and Government Institutions: This category includes universities, research institutions, government agencies, and national libraries worldwide. They are major subscribers to Clarivate's scientific and academic research solutions, such as Web of Science, InCites, and EndNote.
- Life Sciences and Healthcare Companies: This segment comprises pharmaceutical companies, biotechnology firms, medical device manufacturers, and Contract Research Organizations (CROs). They utilize Clarivate's data and analytics for drug discovery, clinical trials, regulatory intelligence, and commercialization strategies, primarily through solutions like Cortellis.
- Corporations and Professional Services Firms: This broad category includes law firms, financial institutions, patent offices, and corporate R&D departments across various industries. These customers leverage Clarivate's intellectual property and innovation intelligence solutions, such as Derwent and CPA Global, for patent searching, trademark protection, and IP management.
AI Analysis | Feedback
nullAI Analysis | Feedback
Jonathan Gear, Chief Executive Officer
Jonathan Gear assumed the role of Chief Executive Officer of Clarivate on September 1, 2022, bringing over two decades of executive leadership experience in technology, data, and information services. Prior to joining Clarivate, Mr. Gear served as the Chief Financial Officer of IHS Markit, where he played a pivotal role in guiding the company through its successful merger with S&P Global. During his 15-year tenure at IHS Markit, he held several senior leadership positions, including President of Resources, Transportation & Consolidated Markets, demonstrating his expertise in driving growth and leading complex business segments. His career also includes leadership roles at Activant Solutions, Inc., smarterwork.com, and Booz Allen Hamilton.
Jonathan Collins, Executive Vice President and Chief Financial Officer
Jonathan Collins joined Clarivate as Executive Vice President and Chief Financial Officer in December 2021. Before his time at Clarivate, Mr. Collins served as Executive Vice President and Chief Financial Officer at Dana Incorporated from March 2016 to December 2021. He also held the position of Senior Vice President and Chief Financial Officer for ProQuest from 2013 to 2016, and Vice President Global Financial Operations at ProQuest from 2010 to 2013.
Gordon Samson, President, Intellectual Property
Gordon Samson was appointed President of Clarivate's Intellectual Property (IP) market segment, effective April 1, 2023. He previously served as Chief Product Officer from February 2022. Mr. Samson joined Clarivate in October 2020 through the acquisition of CPA Global, where he had been Chief Operating Officer since 2014. With over 20 years of experience in senior executive roles, he has a proven track record of driving organizational transformation and growth within the IP industry and beyond.
Jaspal (Jas) Chahal, Chief Legal Officer and General Counsel
Jaspal (Jas) Chahal joined Clarivate as Chief Legal Officer and General Counsel in July 2021. She brings over 25 years of extensive corporate, commercial, and legal experience gained across diverse industries and US-listed information services companies. Ms. Chahal has held various General Counsel roles at organizations such as Brunel University London, IHS Markit, Acxiom Corp, and Sabre Corp.
AI Analysis | Feedback
The key risks to Clarivate's business are as follows:
- High Debt Levels and Liquidity Concerns: Clarivate is burdened by substantial net debt, reported at approximately $6.4 billion with a leverage ratio around 6x EBITDA, which raises concerns about its ability to manage its balance sheet and refinance upcoming debt obligations. A low Altman Z-score further suggests potential financial distress due to a diminishing capacity to reinvest profits or manage debt effectively. Declining free cash flow also limits the company's ability to organically pay down this debt.
- Challenges in Achieving Organic Growth and Integration Issues from Acquisitions: Clarivate is undergoing a significant operational and financial turnaround following years of growth through acquisitions. However, it faces ongoing challenges with negative organic growth, recorded at -1.4% in 2024, and integration issues from past acquisitions. The company's new CEO has initiated a plan focusing on cost-cutting and portfolio simplification to restore growth, but the market remains skeptical. The transition from transactional to subscription-based revenue models also presents short-term challenges, including product suspensions and re-launches, which can impact near-term financial performance.
- Geopolitical Risks due to Operations in Israel: Clarivate faces significant operational risks due to its presence and workforce in Israel, a region characterized by political and military instability. With approximately 500 employees, including key executives based in Israel, escalating hostilities and unrest could disrupt operational continuity. The mandatory military reserve duties for its Israeli employees further compound these risks, complicating the situation during periods of increased regional tension.
AI Analysis | Feedback
The rapid advancement and widespread adoption of sophisticated artificial intelligence (AI) and large language models (LLMs) pose a clear emerging threat to Clarivate. Clarivate's core business relies on providing curated data, advanced analytics, and workflow tools for professionals in research, intellectual property, and life sciences. AI and LLMs, particularly when integrated with retrieval-augmented generation (RAG) and other AI techniques, are increasingly capable of:
- **Automating Information Synthesis and Analysis**: Performing advanced literature reviews, patent landscaping, competitive intelligence, and drug discovery research tasks that traditionally required Clarivate's specialized databases and analytical software.
- **Disintermediation**: Enabling researchers and professionals to derive insights directly from public, open-access, and semi-public datasets using AI tools, potentially reducing the reliance on Clarivate's proprietary, subscription-based platforms.
- **Lowering Barriers to Entry**: Allowing new, agile competitors to offer specialized, AI-driven information services at potentially lower costs or with more intuitive interfaces, directly challenging Clarivate's market position.
AI Analysis | Feedback
Clarivate (symbol: CLVT) operates within a global "innovation lifecycle management" market. The total addressable market (TAM) for this sector is estimated to be over $100 billion, with a projected growth rate of 10%.
The company's serviceable addressable market (SAM), which represents the portion of the TAM currently served by Clarivate's solutions, is approximately $25 billion, with an anticipated growth rate of 6%. Clarivate's main products and services cater to three primary segments: Academia & Government, Intellectual Property, and Life Sciences & Healthcare.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Clarivate (CLVT)
Over the next 2-3 years, Clarivate (CLVT) is expected to drive future revenue growth through several key initiatives and market trends:
- Expansion of Recurring Subscription Revenue and Annual Contract Value (ACV): Clarivate's management has consistently highlighted its commitment to increasing its core subscription and recurring revenue mix. The company has demonstrated sequential and year-over-year improvements in organic Annual Contract Value (ACV) and renewal rates, indicating a focus on expanding its stable, predictable revenue streams.
- AI-Driven Product Innovation and New Launches: Clarivate is heavily investing in and introducing new AI-powered capabilities and products across its key segments, including Life Sciences & Health and Academia & Government. This strategic focus on artificial intelligence is intended to accelerate organic ACV and recurring revenue growth by enhancing existing offerings and creating new value for customers.
- Portfolio Optimization and Strategic Disposals: The company is actively rationalizing its solutions portfolio by divesting non-core products and services. While these disposals may lead to short-term revenue adjustments, the long-term goal is to optimize the business model, improve the mix of higher-margin recurring revenue, and drive more sustainable and profitable growth.
- Growth in Key Market Segments: Clarivate anticipates revenue growth from specific high-potential segments. The company has reported organic ACV growth in its Academia & Government and Life Sciences & Health divisions. Additionally, there has been a notable return to growth in the Intellectual Property segment's patent renewal business, which contributes to recurring revenue.
- Strategic Price Increases: Price adjustments are contributing to Clarivate's organic ACV growth. The company has indicated that price increases have been a factor in the growth of its annualized contract value.
AI Analysis | Feedback
Share Repurchases
- In May 2023, Clarivate's Board of Directors extended its share repurchase authorization through December 31, 2024, and reduced the authorized amount from $1 billion to $500 million.
- A new share repurchase program of up to $500 million was authorized in December 2024, covering the period from January 1, 2025, through December 31, 2026. This new program replaced the prior one.
- Under the program that terminated on December 31, 2024, Clarivate repurchased $300 million of ordinary shares, including $200 million during the third and fourth quarters of 2024. Through the first nine months of 2025, the company repurchased approximately 34.8 million shares, totaling around $150 million.
Share Issuance
- In June 2024, Clarivate converted its preferred shares into 55.3 million shares of common stock.
Outbound Investments
- Clarivate acquired Decision Resources Group for $950 million in January 2020.
- The company completed the acquisition of CPA Global in October 2020.
- In May 2021, Clarivate acquired ProQuest for $5.3 billion.
Capital Expenditures
- Clarivate's capital expenditures for the last 12 months, as of November 2025, amounted to approximately -$274.70 million.
- Historically, capital expenditures have ranged between 6% and 9% of revenues, with 2023 projected at approximately 9% of revenues.
- The primary focus of capital expenditures has been on capitalized labor, contract services, and other costs associated with product and content development.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| CLVT Dip Buy Analysis | 07/10/2025 | |
| Clarivate (CLVT) Valuation Ratios Comparison | 05/15/2025 | |
| Clarivate Total Shareholder Return (TSR): -45.1% in 2024 and -40.0% 3-yr compounded annual returns (below peer average) | 03/07/2025 | |
| null | 12/15/2024 | |
| Day 5 of Gains Streak for Clarivate Stock with 32% Return (vs. -38% YTD) [11/25/2024] | 11/25/2024 | |
| Clarivate Market Price | 11/25/2024 | |
| Day 5 of Gains Streak for Clarivate Stock with 32% Return (vs. -38% YTD) [11/23/2024] | 11/23/2024 | |
| Clarivate vs. S&P500 Correlation | 10/03/2024 | |
| Clarivate Price Volatility | 09/24/2024 | |
| Fundamental Metrics: ... | 06/19/2024 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 207.47 |
| Mkt Cap | 34.3 |
| Rev LTM | 5,203 |
| Op Inc LTM | 1,737 |
| FCF LTM | 1,469 |
| FCF 3Y Avg | 1,406 |
| CFO LTM | 1,904 |
| CFO 3Y Avg | 1,818 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.6% |
| Rev Chg 3Y Avg | 8.4% |
| Rev Chg Q | 6.4% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Mgn LTM | 36.0% |
| Op Mgn 3Y Avg | 33.8% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 34.8% |
| CFO/Rev 3Y Avg | 34.7% |
| FCF/Rev LTM | 29.7% |
| FCF/Rev 3Y Avg | 29.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 34.3 |
| P/S | 7.2 |
| P/EBIT | 18.6 |
| P/E | 26.3 |
| P/CFO | 18.4 |
| Total Yield | 4.1% |
| Dividend Yield | 0.9% |
| FCF Yield 3Y Avg | 2.9% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -17.7% |
| 3M Rtn | -12.3% |
| 6M Rtn | -35.1% |
| 12M Rtn | -38.8% |
| 3Y Rtn | -5.7% |
| 1M Excs Rtn | -17.4% |
| 3M Excs Rtn | -13.6% |
| 6M Excs Rtn | -43.9% |
| 12M Excs Rtn | -54.0% |
| 3Y Excs Rtn | -76.0% |
Price Behavior
| Market Price | $2.17 | |
| Market Cap ($ Bil) | 1.5 | |
| First Trading Date | 10/29/2018 | |
| Distance from 52W High | -58.1% | |
| 50 Days | 200 Days | |
| DMA Price | $3.29 | $3.84 |
| DMA Trend | down | down |
| Distance from DMA | -34.0% | -43.5% |
| 3M | 1YR | |
| Volatility | 60.2% | 54.1% |
| Downside Capture | 347.89 | 216.36 |
| Upside Capture | 47.24 | 96.88 |
| Correlation (SPY) | 37.9% | 52.9% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.42 | 1.68 | 1.51 | 1.44 | 1.45 | 1.33 |
| Up Beta | 1.00 | 1.02 | 1.51 | 1.67 | 1.44 | 1.24 |
| Down Beta | 3.17 | 2.64 | 1.34 | 1.35 | 1.38 | 1.37 |
| Up Capture | -60% | -73% | 69% | 69% | 94% | 74% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 6 | 15 | 26 | 60 | 110 | 337 |
| Down Capture | 501% | 307% | 214% | 186% | 143% | 111% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 13 | 25 | 33 | 60 | 131 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -57.9% | 54.1% | -1.41 | - |
| Sector ETF (XLK) | 22.0% | 27.1% | 0.71 | 45.3% |
| Equity (SPY) | 15.9% | 19.2% | 0.64 | 52.8% |
| Gold (GLD) | 76.1% | 24.5% | 2.27 | -14.7% |
| Commodities (DBC) | 9.3% | 16.5% | 0.36 | 9.2% |
| Real Estate (VNQ) | 4.6% | 16.5% | 0.10 | 45.6% |
| Bitcoin (BTCUSD) | -24.7% | 40.5% | -0.60 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -40.4% | 51.6% | -0.80 | - |
| Sector ETF (XLK) | 16.8% | 24.7% | 0.61 | 39.7% |
| Equity (SPY) | 14.2% | 17.0% | 0.66 | 45.3% |
| Gold (GLD) | 21.5% | 16.8% | 1.04 | 4.4% |
| Commodities (DBC) | 12.1% | 18.9% | 0.52 | 4.7% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 43.2% |
| Bitcoin (BTCUSD) | 18.0% | 57.4% | 0.52 | 15.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CLVT | |
|---|---|---|---|---|
| CLVT | -13.7% | 47.9% | -0.24 | - |
| Sector ETF (XLK) | 22.8% | 24.2% | 0.86 | 39.7% |
| Equity (SPY) | 15.7% | 17.9% | 0.75 | 42.8% |
| Gold (GLD) | 15.6% | 15.5% | 0.84 | 7.5% |
| Commodities (DBC) | 8.3% | 17.6% | 0.39 | 9.6% |
| Real Estate (VNQ) | 5.9% | 20.8% | 0.25 | 39.6% |
| Bitcoin (BTCUSD) | 69.3% | 66.5% | 1.09 | 15.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2025 | -4.1% | -4.4% | 3.0% |
| 7/30/2025 | -4.3% | -12.8% | 5.9% |
| 2/19/2025 | -1.4% | -7.5% | -9.1% |
| 11/6/2024 | -27.2% | -30.3% | -13.4% |
| 8/6/2024 | -12.2% | -10.4% | 9.8% |
| 5/8/2024 | -11.4% | -6.2% | -17.1% |
| 1/22/2024 | -0.2% | -3.0% | -3.1% |
| 11/7/2023 | 3.0% | -4.0% | 17.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 4 | 6 | 8 |
| # Negative | 16 | 14 | 12 |
| Median Positive | 4.9% | 4.1% | 3.9% |
| Median Negative | -6.9% | -6.4% | -11.6% |
| Max Positive | 12.7% | 7.3% | 17.3% |
| Max Negative | -27.2% | -30.3% | -25.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/29/2025 | 10-Q |
| 12/31/2024 | 02/19/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/10/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Veinstein, Bar | President, A&G | Direct | Sell | 12022025 | 3.74 | 309,902 | 1,159,033 | 3,174,553 | Form |
| 2 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.38 | 500,000 | 1,690,000 | 2,619,500 | Form | |
| 3 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 11032025 | 3.52 | 225,000 | 792,000 | 3,520,000 | Form | |
| 4 | Snyder, Andrew Miles | Cambridge Information Group I LLC | Buy | 11032025 | 3.33 | 1,460,000 | 4,861,800 | 7,484,208 | Form | |
| 5 | Cornick, Kenneth L | Cornick Family Investor, LLC | Buy | 8052025 | 3.74 | 165,000 | 617,100 | 1,028,500 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.